NCT05246280 - Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA | Biotech Hunter

Enrollment

169

Participants

Timeline

Start Date

March 2, 2022

Primary Completion Date

July 9, 2024

Study Completion Date

July 9, 2024

Conditions

Rheumatoid Arthritis

Interventions

DRUG

TC99m-tilmanocept

Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.

Trial Locations (13)

Altoona Center for Clinical Research, Duncansville

Life Clinical Trials, Margate

Believe Clinical Trials, Coral Springs

D&H National Research Centers, Inc, Miami

Nouvelle Clinical Research, Cutler Bay

Highlands Advanced Rheumatology and Arthritis Center, Avon Park

Vida Clinical Research, Kissimmee

Advanced Clinical Research of Orlando, Ocoee

Physician Research Collaboration, Lincoln

Essential Medical Research, Tulsa

Arthritis and Osteoporosis Center of Coastal Bend, Corpus Christi

Attune Health Research, Beverly Hills

University of California, San Francisco, San Francisco